Self-Report Daily Life Activity as a Prognostic Marker of Idiopathic Pulmonary Fibrosis by Leuchte, Hanno H. et al.
E-Mail karger@karger.com
 Clinical Investigations 
 Respiration 2015;90:460–467 
 DOI: 10.1159/000441302 
 Self-Report Daily Life Activity as 
a Prognostic Marker of Idiopathic 
Pulmonary Fibrosis 
 Hanno H. Leuchte  a, b    Philip Mernitz  a    Carlos Baezner  a    
Rainer A. Baumgartner  a, b    Werner von Wulffen  a    Claus Neurohr  a    
Juergen Behr  a   
 a   Department of Internal Medicine V, Asklepios Fachkliniken München-Gauting, Comprehensive Pneumology 
Center, Ludwig Maximilians University, Klinikum Grosshadern, and  b   Department of Internal Medicine II, 
Neuwittelsbach Hospital,  Munich , Germany
 
pairment and inversely correlated to the 6MWD. Thirty-two 
patients were in AC I/II, 98 in AC III and 26 patients in AC IV. 
Thirty-seven (23.7%) patients died during a median follow-
up of 14.9 months, comprising 1 patient in AC I/II. In addition, 
a 6MWD <470 m predicted mortality. Combining AC I/II and 
a 6MWD >470 m identified a subgroup of patients with fa-
vorable outcome.  Conclusions: AC is a novel scoring system 
which can easily be obtained and correlates with lung func-
tional and physical impairments as well as mortality. More-
over, AC adds prognostic information to the 6MWD. 
 © 2015 S. Karger AG, Basel 
 Introduction 
 Idiopathic pulmonary fibrosis (IPF) is an incurable 
and progressive disease leading to respiratory insufficien-
cy with consecutive functional impairment and death, 
usually within 3–5 years  [1, 2] . Despite new therapeutic 
options, satisfactory medical therapies are lacking  [3, 4] , 
and lung transplantation remains the ultimate therapeu-
tic alternative in selected patients  [5, 6] . However, the 
clinical course and survival is widely variable and donor 
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 Abstract 
 Background: Idiopathic pulmonary fibrosis (IPF) is a pro-
gressive disease, leading to substantial physical impairment. 
The distance walked in 6 min (6MWD) is a measure of exer-
cise tolerance and is of prognostic relevance in IPF. While 
6MWD is a punctual measurement which may not be repre-
sentative, self-reported daily life activity may represent the 
patients’ functional capacity more globally even in less se-
vere affected patients.  Objectives: We evaluated and char-
acterized a simple classification system based on the pa-
tients’ self-reported daily activity and analyzed if this would 
add significantly to the prognostic information of the 6MWD 
alone in IPF patients.  Methods: Daily life activity was as-
sessed in IPF (n = 156) patients with standardized questions 
and categorized in activity classes (AC I–IV), comprising the 
less severe impaired in AC I and II. The 6MWD was also as-
sessed.  Results: ACs were related to the lung functional im-
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organs are limited  [7] . Therefore, individual risk stratifi-
cation has been attempted. This has mainly been based on 
scores that use and/or combine clinical and lung func-
tional parameters, radiographic findings as well as exer-
cise parameters  [8–12] .
 Dyspnea and exercise limitation are the main com-
plaints of patients with IPF, leading to reduced physical 
capacity and social activities. While exercise limitation 
may be multifactorial in the individual patient, it can be 
objectified measuring the distance walked during the 
6-min walk test (6MWD)  [13] which is of prognostic rel-
evance in selected IPF patients evaluated for lung trans-
plantation  [14] . It remains unclear whether the 6MWD 
alleviates prognostication also in a population outside the 
transplantation window. In addition, the 6MWD is a 
point-in-time measurement and underlies considerable 
variability and, therefore, it could be questioned, whether 
additional prognostic information can be retrieved from 
a more general assessment of functional capacity.
 Disease severity of IPF and comorbidities seem to have 
an impact on the average physical capacity of IPF patients 
in daily life. This could be especially true for those pa-
tients being less severely affected with regard to lung 
function or radiographic parameters. However, although 
it seems reasonable to quantify impairment of average 
daily life activities, a structured quantification of IPF pa-
tients’ daily life activities has not been attempted so far.
 We sought to characterize two easy-to-obtain param-
eters that reflect functional impairment in a singular 
(6MWD) and an average (daily life activity) fashion and 
relate these parameters to outcome in a nonpreselected 
cohort of IPF patients.
 Therefore, we intended to define a prognostic threshold 
value of the 6MWD in a less advanced IPF population. Sec-
ond, we sought to establish a simple classification of self-
reported daily life activities and to relate this to mortality 
of IPF patients with a wide range of disease severity. Fi-
nally, we analyzed whether the combination of these two 
parameters provides additional prognostic information.
 Methods 
 Patient Selection 
 In this prospective study, 156 consecutive IPF patients who 
were diagnosed in accordance to the ATS criteria  [15] were in-
cluded during their first visit to our tertiary referral center between 
March 2008 and March 2012. The diagnosis was based on histo-
pathologic and radiographic findings in 90 patients and 66 patients 
solely had typical radiographic characteristics on high-resolution 
CT. All patients were evaluated for potential lung transplantation.
 Patients with significant comorbidities that would significantly 
affect survival (such as malignant and/or significant cardiovascu-
lar disease) were excluded as were patients not being able to per-
form the 6-min walk test due to orthopedic reasons. Finally, pa-
tients (n = 13) with very advanced disease who were not able to 
perform basic personal hygiene as a minimum of inquired daily life 
activity were excluded.
 Treatments at the time point of inclusion varied with an over-
lap between supportive care, no specific therapies, cortisone (usu-
ally prednisolone), high-dose acetylcysteine, azathioprine and cy-
clophosphamide. Since we did not perform a prospective treat-
ment trial with predefined treatment regimen, we were not able to 
evaluate different therapeutic effects.
 The study involved no specific interventions but a standardized 
protocol that reflected our clinical practice and was in accordance 
with our local ethic committee requirements.
 Assessment of Activity Class 
 All patients were asked the following simple questions reflect-
ing their functional capacity in daily life, such as: ‘Are you able to 
perform basic personal hygiene?’; ‘Are you able to perform light 
housework?’; ‘Are you physically capable to work on a regular ba-
sis?’, while the capability of performing all housework was scored 
equal; ‘Are you able to participate in sports?’, while manual labor 
that requires physical activity was considered equal.
 When all 4 questions were affirmed, a patient was classified as 
daily activity class (AC) I, answering 3 questions with ‘yes’ quali-
fied for AC II, 2 positive votes for AC III and the capability of per-
forming personal hygiene was scored as AC IV. As mentioned 
above, patients who were not able to perform personal basic hy-
giene were excluded from the study. Assessment was done, before 
any supervised training or rehabilitation program was started (on-
line suppl. fig. 1; see www.karger.com/doi/10.1159/000441302).
 Six-Minute Walk Test 
 All patients conducted this test according to the ATS and sup-
plemental oxygen was allowed for patients who were on long-term 
oxygen therapy (n = 99)  [13] .
 Lung Function Test 
 Standard parameters, such as total lung capacity (TLC) and 
forced vital capacity (FVC) were measured with spirometry and 
body plethysmography from all patients. Blood gas analysis (with-
out supplemental oxygen) was performed in arterialized capillary 
blood from the ear lobe. The diffusing capacity for carbon monox-
ide (D LCO ) was measured employing the single breath method 
(n = 138). All parameters included were calculated as percent of 
the individual predicted value  [16] .
 Survival Estimates 
 The individual observation period began with the first exami-
nation/test and ended when the patient either died (n = 37) or re-
ceived lung transplantation (n = 60). Those who received lung 
transplantation were included as ‘alive’ until the day of transplan-
tation and censored thereafter. All nonsurvivors died of cardiore-
spiratory failure. No patient was lost to follow-up.
 Statistical Analysis 
 Data are shown as mean and standard error of mean and/or 
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performed using the Pearson or the Spearman rho procedure, ac-
cording to the distribution of parameters. Depending on the nor-
mal distribution, a comparison between two groups was per-
formed using Student’s t test for unpaired samples or the Mann-
Whitney U test, respectively. For a comparison of more than two 
groups, a one-way ANOVA test with Bonferroni correction for 
multiple testing was conducted.
 The prognostic value of each variable was tested by univariate 
COX proportional hazards regression analysis followed by a step-
wise multivariate analysis. Survival was derived from Kaplan-Mei-
er curves. In general, a p value <0.05 was considered statistically 
significant. The software used for statistical calculation was SPSS 
15.0 for Windows ® .
 Results 
 Characterization of Daily AC ( Table 1 ) 
 Demographic data were equally distributed between the 
different ACs. Patients in ACs I and II had a limited disease 
with slight-to-moderate lung functional impairment and 
blood gases. The majority of patients were classified as AC 
III (63%). In this group, patients already had a severe re-
strictive impairment (FVC 54.1%pred) with a significant 
diffusion deficit (D LCO 27.5%) and hypoxemia at rest.
 Overall, ACs were correlated with the lung functional 
impairment (AC vs. FVC %pred: r = –0.43, AC vs. TLC 
%pred: r = –0.4), diffusion capacity for carbon monoxide 
(AC vs. D LCO %pred: r = –0.6), hypoxemia (AC vs. p O 2 : 
r = –0.59) and the 6MWD (AC vs. 6MWD: r = –0.67) (all 
p < 0.001). AC and age were not correlated.
 Characteristics of Survivors versus Nonsurvivors and 
Lung Transplant Recipients ( Tables 2 ,  3 ) 
 The overall mean observation time was 21.6 months 
(median 14.9; minimum 0.2, maximum 79.9).
 Demographic data, lung function parameters and the 
6MWD of the whole study population are included in 
 table 2 . Overall, patients had significant restrictive func-
tional impairment, reduced D LCO and hypoxemia. Lung 
function was slightly less affected in the surviving pa-
tients. However, this did not reach statistical significance. 
Patients who died during the observational period re-
ceived long-term oxygen therapy more often and the 
6MWD was significantly lower. The distribution of AC 
between survivors and patients who died was not signifi-
cantly different.
 A comparison between patients who received lung 
transplantation during follow-up and those who did not 
revealed a significantly more severe lung function impair-
ment and lower 6MWD.
 AC and 6MWD as Predictors of Mortality 
 In the univariate analysis, a 6MWD <470 m and an 
AC >II were associated with a 2.9-fold (1.2–7.1) and 16.9-
fold (2.3–123.6) mortality risk, during a median follow-
up of 14.9 months. Independent of the AC, a 6MWD 
<470 m was still a predictor of mortality during multi-
variate analysis [hazard ratio 1.8 (1.1–4), p < 0.05].
 In terms of a potential survival benefit, we calculated 
the hazard ratio for a 6MWD  ≥ 470 m and an AC <III. 
 Table 1. Characteristics of ACs
Study population
(n = 156, 100%)
AC I
(n = 2, 1.3%)
AC II
(n = 30, 19.2%)
AC III
(n = 98, 62.8%)
AC IV
(n = 26, 16.7%)
Age, years 55.8 ± 0.8 49.7 ± 13.3 57.9 ± 1.9 55.8 ± 1.0 53.8 ± 1.8
Weight, kg 74.4 ± 1.6 66.0 82.0 ± 4.2 73.1 ± 2.0 77.8 ± 3.3
Gender (m/f) 97/59 1/1 22/8 56/42 18/8
Lung function
FVC, l 2.04 ± 0.1 3.1 ± 0.4 2.8 ± 0.1*** 1.9 ± 0.1 1.5 ± 0.1***
FVC, % 55.6 ± 1.9 74.9 ± 10.1 73.0 ± 3.8*** 54.1 ± 2.4 39.3 ± 2.3***
TLC, l 3.4 ± 0.1 4.7 ± 0.2 4.2 ± 0.2*** 3.2 ± 0.1* 2.8 ± 0.2**
TLC, % 55.7 ± 1.4 72.0 ± 3.6 67.1 ± 3.2*** 54.5 ± 1.6 45.6 ± 2.2***
DLCO 2.9 ± 0.1 6.6 ± 0.7*** 4.3 ± 0.3*** 2.4 ± 0.1*** 1.9 ± 0.1***
DLCO, % 31.8 ± 1.4 67.6 ± 11.3 47.9 ± 3.0*** 27.5 ± 1.3*** 20.6 ± 1.7***
pO2, mm Hg 56.0 ± 1.0 75.0 ± 8.0 67.4 ± 3.2*** 53.8 ± 1.2* 49.3 ± 2.6*
LTOT, n (%) 99 none 4 (13.3) 69 (70.4) 26 (100)
6MWD, m 331 ± 12.2 545 ± 25.3* 482 ± 16.3*** 323 ± 12.1*** 166 ± 22.3***
LTOT = Long-term oxygen therapy. * p < 0.05; ** p < 0.01; *** p < 0.001. Comparisons are performed between 
the study population and the respective AC.
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While an AC <III alone was associated with a survival 
benefit [hazard ratio 0.06 (0.01–0.4), p < 0.01], a 6MWD 
 ≥ 470 m was not associated with a statistically significant 
survival benefit. However, combining these two param-
eters revealed a significant survival benefit for those pa-
tients in AC <III who were able to walk  ≥ 470 m during 
the walk test [n = 19, hazard ratio 0.1 (0.02–0.9); p < 
0.05].
 Survival Estimates 
 Survival Estimates Based on AC ( Fig. 1 ). Thirty out of 
156 patients ( ∼ 19%) were classified as AC II. One patient 
died, resulting in an estimated mean survival time of 77.6 
± 2.3 months in this group. Ninety-eight patients ( ∼ 63%) 
were in AC III with a mean survival time of 49.4 ± 4.6 
months (median 62; 95% CI 32.6–91.4). Twenty-five 
( ∼ 25%) patients in this class died during the follow-up. 
Finally, AC IV comprised 26 patients ( ∼ 17%) and 11 pa-




(n = 119, 76.3%)
Nonsurvivors
(n = 37, 23.7%)
p value
Age, years 55.8 ± 0.8 55.2 ± 1.0 57.6 ± 1.5 n.s.
Weight, kg 74.4 ± 1.6 75.5 ± 2.0 72.6 ± 2.5 n.s.
Gender (m/f) 97/59 73/47 24/14 n.s.
Lung function
FVC, l 2.0 ± 0.1 2.1 ± 0.1 1.8 ± 0.1 n.s.
FVC, % 55.6 ± 1.9 56.4 ± 2.1 52.6 ± 4.5 n.s.
TLC, l 3.4 ± 0.1 3.5 ± 0.1 3.2 ± 0.2 n.s.
TLC, % 55.7 ± 1.4 56.5 ± 1.7 53.0 ±2.2 n.s.
TLCO 2.9 ± 0.1 2.9 ± 0.1 2.5 ± 0.3 n.s.
TLCO, % 31.8 ± 1.4 32.8 ± 1.6 28.1 ± 2.5 n.s.
pO2, mm Hg 56.0 ± 1.0 56.7 ± 1.2 53.6 ± 2.3 n.s.
LTOT, n (%) 99 (63.5) 68 (57.1) 31 (81.7)
AC assessment
AC I, n 2 2 0
Mean observation time,
months 39.2 [6.6 – 71.9] 39.2 [6.6 – 71.9] n.a. [n.a.] n.a.
AC II, n 30 29 1
Mean observation time,
months 34.2 [5.9 – 79.9] 35.2 [13.8 – 79.9] 5.9 [n.a.] n.s.
AC III, n 98 73 25
Mean observation time,
months 19.9 [0.2 – 77.5] 21.3 [0.2 – 77.5] 15.8 [3 – 62] n.s.
AC IV, n 26 15 11
Mean observation time,
months 11.8 [0.8 – 46.7] 13.4 [0.8 – 46.7] 9.2 [1.9 – 28.2] n.s.
6MWD, m 331 ± 11.7 350 ± 12.8 271 ± 25.2 <0.01
 LTOT = Long-term oxygen therapy; n.a. = not available. Figures in square brackets indicate ranges.












Age, years 55.8 ± 0.8 51.2 ± 1.0 58.6 ± 1.0 n.s.
Weight, kg 74.4 ± 1.6 77 ± 2.4 72 ± 2.1 n.s.
Gender (m/f) 97/59 37/22 60/37 n.s.
Lung function
FVC, l 2.0 ± 0.1 1.7 ± 0.1 2.2 ± 0.1 <0.001
FVC, % 55.6 ± 1.9 43.9 ± 2.0 62.9 ± 2.6 <0.001
TLC, l 3.4 ± 0.1 2.9 ± 0.1 3.7 ± 0.1 <0.001
TLC, % 55.7 ± 1.4 47.5 ± 1.9 60.9 ± 1.7 <0.001
TLCO 2.9 ± 0.1 2.4 ± 0.2 3.1 ± 0.2 <0.005
TLCO, % 31.8 ± 1,4 25.8 ± 1.8 35.6 ± 1.8 <0.001
pO2, mm Hg 56.0 ± 1.0 51.7 ± 1.6 58.6 ± 1.3 <0.005
LTOT, n (%) 99 (63.5) 50 (84.7) 49 (50.5) n.s.
6MWD, m 331 ± 11.7 301 ± 17.1 349 ± 15.5 <0.05
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tients out of this group ( ∼ 46%) died with a mean surviv-
al time of 22.9 ± 4.5 months (median 11.6; 95% CI 1.2–
46.9). Comparison between groups revealed statistical 
significance (p < 0.001).
 Survival Estimates Based on the 6MWD ( Fig. 2 ). One 
hundred and twenty-six patients ( ∼ 81%) had a 6MWD 
<470 m, while 30 patients performed better. Thirty-two 
patients ( ∼ 25%) in the 6MWD <470 m group died during 
an estimated mean survival of 47.9 ± 4.6 (median 62; 95% 
CI 37.5–86.5) months, whereas only 5 patients (17%) of 
those who walked  ≥ 470 m died with an estimated mean 
survival time of 67 ± 5.2 months (p < 0.05).
 Survival Estimates Based on a Combination of AC and 
6MWD ( Fig.  3 ). A subgroup of 19 patients ( ∼ 12%) in 
AC <III was able to perform a 6MWD  ≥ 470 m. One pa-
tient out of this group died and the estimated mean sur-
vival was 76 ± 3.8 months. Thirty-six of the remaining 137 
patients died with a mean survival time of 49.4 ± 4.1 
months (median 62; 95% CI 33.1–90.9; p < 0.05).
 Discussion 
 In this study, we propose AC as a novel classification of 
global functional impairment with prognostic relevance 
in IPF patients. AC comprises 4 classes (I–IV) based on 
the patients’ self-reported daily life activity, including the 
less severe in AC I and the most severe in AC IV. AC is 
understood as a measure of the average physical perfor-
mance status of patients with IPF, balancing daily fluctua-
tions. Therefore, we characterize AC as a marker of dis-
ease severity and prognosis in a reasonable cohort of IPF 
patients. In addition, we observed that in a nonpreselected 
cohort a 6MWD below 470 m already identifies a sub-
group of IPF patients with worse prognosis. The combina-
tion of both an AC <III and a 6MWD  ≥ 470 m identified 
a subgroup of IPF patients with a favorable outcome.
 Different tools for the risk stratification of IPF patients 
have been suggested including clinical, lung functional 
and radiographic data  [1, 2, 10, 14] . However, variability 
of symptoms may have a negative impact on a single mea-
surement of the 6MWD and may also influence physio-
 Fig. 1. AC and overall survival in IPF. Impact of the functional 
classes on overall survival in IPF. 
 Fig. 2. Six-min walk test and survival in IPF. Impact of a 6MWD 
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6MWD ≥470 m 30 24 17 10 8 5 3
6MWD <470 m 126 73 40 18 7 5 1
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AC II 30 29 23 13 5 4 2
AC III 98 57 30 13 10 6 2
AC IV 26 9 4 2 0 0 0
Sum 154 95 57 28 15 10 4
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logical measurements. Therefore, a marker that reflects 
average physical performance status could add signifi-
cantly to a singular physiologic measure. Accordingly, 
AC was established to facilitate the assessment of the 
physical capabilities and disabilities and hence the func-
tional status of these patients, averaging fluctuations. 
Thereby, AC includes not only dyspnea as a major com-
plaint of IPF patients, but also integrates an additional 
aspect of the disease and, therefore, provides more infor-
mation as compared to a dyspnea questionnaire or clas-
sification alone (e.g. NYHA class or MRC score). How-
ever, AC is not a replacement of valuable questionnaires 
for respiratory diseases, e.g. the St. George’s Respiratory 
Questionnaire (SGRQ)  [17, 18] , which calculates 3 com-
ponent scores out of 76 items, concerning symptoms, ac-
tivity, and impacts (on daily life). This and other ques-
tionnaires have been used in clinical IPF trials  [4, 19, 20] . 
However, implementation of such questionnaires into 
daily routine is often not feasible.
 In contrast, AC is based on 4 standardized questions 
and the number of positive answers can simply be con-
verted into 4 classes of daily life impairment (AC I–IV). 
In this current study, AC served as a marker of disease 
severity of IPF and had a good (inverse) correlation with 
lung functional parameters and the 6MWD. Moreover, 
patients in AC III or IV had a worse observed outcome as 
compared to those in AC I or II. Finally, when AC I or II 
patients were able to walk  ≥ 470 m, this indicated an ad-
ditional survival benefit. Although intuitively we cannot 
demonstrate that keeping or reestablishing functional ca-
pacity (i.e. AC I or II) would affect outcome in IPF, this 
seems to be a reasonable treatment goal for future studies. 
However, although we cannot conclude how transition of 
a worse to a better AC would impact individual progno-
sis, we think that staying in an AC III or IV should be 
considered as a parameter of worse clinical outcome and, 
therefore, should include lung transplantation as a thera-
peutic option for eligible patients.
 Another aspect of this study was to characterize the 
prognostic value of the 6MWD in a nonpreselected co-
hort, comprising less affected IPF patients as well as pa-
tients who are already candidates for lung transplanta-
tion.
 Our study cohort incorporated patients with a wide 
range of functional impairment and in this heteroge-
neous group of IPF patients, a 6MWD  ≥ 470 m was a pos-
itive predictor of survival during a median follow-up pe-
riod of 14.9 months. We think that this emphasizes the 
value of this functional test in severely but also in mild-
to-moderately affected IPF patients.
 The 6-min walk test is an easy, inexpensive, safe, and 
reproducible submaximal exercise test in chronic lung 
disease, including IPF  [13] . The distance walked during 
this test is of prognostic significance in severely affected 
IPF patients waiting for lung transplantation  [14] . Varia-
tions (e.g. the timed walk test  [21] ) and special aspects of 
this test, such as the desaturation that occurs during the 
walk test or the longitudinal development, add signifi-
cantly in terms of estimation of prognosis in mixed col-
lectives of idiopathic interstitial pneumonias  [22] and IPF 
populations  [11, 23] . However, with regard to desatura-
tion, there is still some uncertainty, since the applied test 
protocols vary, especially with respect to the use of sup-
plemental oxygen during the test. In addition, to stop the 
test whenever oxygen saturation falls below 87% (or any 
other cutoff value) could interfere with the distance 
walked, while the safety aspect is unproven. In addition, 
from our experience, measuring transcutaneous satura-
tion during the test may be hampered by technical diffi-
culties and the reproducibility is low. Since this is a sub-
maximal exercise test, and the test person is urged to per-
 Fig. 3. Combination of the AC and the 6MWD and its impact on 
survival in IPF. Impact of the AC and the 6MWD cutoff value of 
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form at her or his own speed, it seems to be plausible that 
patients require more physical exercise during not super-
vised daily activities as compared to this walk test. What-
soever, without controlling transcutaneous saturation, 
the walk test was a safe test in our study population com-
prising mild but also severely affected patients. Neverthe-
less, due to the fact that we did not measure saturation in 
our patients during the test, we cannot conclude on dis-
tance-desaturation products or similar parameters.
 Our results are in line with the findings of Lederer et 
al.  [14] who reported the impact of the 6MWD on prog-
nosis of IPF patients who were already listed for lung 
transplantation during a median follow-up of 4 months. 
Study objects in our trial were very differently affected 
from IPF and not uniformly listed for lung transplanta-
tion at study entry. This gave us the opportunity to report 
already a distance of 470 m to be of prognostic relevance 
during a median follow-up of 14.9 months. The differ-
ence between the two study populations is even more ob-
vious, since patients with a 6MWD >396 m were included 
in the best quartile of the earlier study, but even patients 
with a 6MWD of up to 470 m had an increased mortality 
in our study.
 Our study has clear limitations. First, this is an obser-
vational study which does not allow concluding on any 
therapeutic effects. Second, although we included a mixed 
population with regard to functional impairment, pa-
tients were initially evaluated and were definitive candi-
dates for lung transplantation at some time point, taking 
into account the severely impaired prognosis. This might 
blur our observation, since we might not appropriately 
cover the whole spectrum of IPF severities. However, a 
significant portion of 20% of the patients was only mild-
to-moderately affected. In addition, our observations are 
not driven by the most conceivable severe IPF patients 
who were excluded from the study. This is also under-
lined by the fact that we report a rather high cutoff of the 
6MWD of 470 m to be of prognostic value in this popula-
tion. Also, the rather young age of our population could 
have biased our observation, and it may not be self-evi-
dent that the data of the 6MWD may be transferred to the 
‘typical age’ IPF cohort. Also, the high number of com-
bined histological and radiological assessment in our 
study has to be interpreted in the context of the rather 
‘atypical age’ IPF cohort. We are also aware of the fact that 
the AC is influenced by the individual perception and co-
factors such as depression, especially as we demonstrate 
a large variability of (lung) functional data within the AC. 
In addition, comorbidities (e.g. pulmonary hypertension) 
may have influenced AC and the 6MWD besides lung 
functional impairment. However, we think that it is ad-
vantageous to integrate different disease aspect in the AC, 
although we are not able to differentiate the driving fac-
tors leading to a reduction of daily life activity. Finally, we 
did not compare AC with other disease activity scores.
 Despite these limitations, we suggest the AC score as 
an inexpensive and independent test that can easily be 
integrated in daily practice, providing prognostic infor-
mation alone and in combination with the 6MWD.
 Acknowledgements 
 We thank Elisabeth Becker and her team for excellent technical 
support. This work contains a significant portion of the doctoral 
thesis of Mr. Philipp Mernitz at the LudwigMaximilian University 
of Munich, Germany.
 Financial Disclosure and Conflicts of Interest 




 Daily Life Activity in IPF  Respiration 2015;90:460–467 
DOI: 10.1159/000441302
467
of changes in physiology and six-minute-walk 
test. Am J Respir Crit Care Med 2006; 174: 
 803–809. 
 12 Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, To-
massetti S, Lee JS, Poletti V, Buccioli M, Elick-
er BM, Jones KD, King TE Jr, Collard HR: A 
multidimensional index and staging system 
for idiopathic pulmonary fibrosis. Ann Intern 
Med 2012; 156: 684–691. 
 13 ATS statement: guidelines for the six-minute 
walk test. Am J Respir Crit Care Med 2002; 
 166: 111–117. 
 14 Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, 
Sonett JR, Kawut SM: Six-minute-walk dis-
tance predicts waiting list survival in idio-
pathic pulmonary fibrosis. Am J Respir Crit 
Care Med 2006; 174: 659–664. 
 15 Raghu G, Collard HR, Egan JJ, Martinez FJ, 
Behr J, Brown KK, Colby TV, Cordier JF, Fla-
herty KR, Lasky JA, Lynch DA, Ryu JH, 
Swigris JJ, Wells AU, Ancochea J, Bouros D, 
Carvalho C, Costabel U, Ebina M, Hansell 
DM, Johkoh T, Kim DS, King TE Jr, Kondoh 
Y, Myers J, Muller NL, Nicholson AG, Richel-
di L, Selman M, Dudden RF, Griss BS, Protz-
ko SL, Schunemann HJ: An official ATS/ERS/
JRS/ALAT statement: idiopathic pulmonary 
fibrosis: evidence-based guidelines for diag-
nosis and management. Am J Respir Crit Care 
Med 2011; 183: 788–824. 
 16 Quanjer PH, Tammeling GJ, Cotes JE, Peder-
sen OF, Peslin R, Yernault JC: Lung volumes 
and forced ventilatory flows. Report Working 
Party Standardization of Lung Function 
Tests, European Community for Steel and 
Coal. Official Statement of the European Re-
spiratory Society. Eur Respir J Suppl 1993; 16: 
 5–40. 
 17 Jones PW, Quirk FH, Baveystock CM: The St 
George’s Respiratory Questionnaire. Respir 
Med 1991; 85(suppl B):25–31; discussion 33–
27. 
 18 Jones PW, Quirk FH, Baveystock CM, Little-
johns P: A self-complete measure of health 
status for chronic airflow limitation. The St. 
George’s Respiratory Questionnaire. Am Rev 
Respir Dis 1992; 145: 1321–1327. 
 19 Raghu G, Brown KK, Bradford WZ, Starko K, 
Noble PW, Schwartz DA, King TE Jr; Idio-
pathic Pulmonary Fibrosis Study Group: A 
placebo-controlled trial of interferon gamma-
1b in patients with idiopathic pulmonary fi-
brosis. N Engl J Med 2004; 350: 125–133. 
 20 Demedts M, Behr J, Buhl R, Costabel U, 
Dekhuijzen R, Jansen HM, MacNee W, Tho-
meer M, Wallaert B, Laurent F, Nicholson 
AG, Verbeken EK, Verschakelen J, Flower 
CD, Capron F, Petruzzelli S, De Vuyst P, van 
den Bosch JM, Rodriguez-Becerra E, Cor-
vasce G, Lankhorst I, Sardina M, Montanari 
M; IFIGENIA Study Group: High-dose acet-
ylcysteine in idiopathic pulmonary fibrosis. N 
Engl J Med 2005; 353: 2229–2242. 
 21 Hallstrand TS, Boitano LJ, Johnson WC, Spa-
da CA, Hayes JG, Raghu G: The timed walk 
test as a measure of severity and survival in 
idiopathic pulmonary fibrosis. Eur Respir J 
2005; 25: 96–103. 
 22 Lama VN, Flaherty KR, Toews GB, Colby TV, 
Travis WD, Long Q, Murray S, Kazerooni EA, 
Gross BH, Lynch JP 3rd, Martinez FJ: Prog-
nostic value of desaturation during a 6-min-
ute walk test in idiopathic interstitial pneu-
monia. Am J Respir Crit Care Med 2003; 168: 
 1084–1090. 
 23 Lettieri CJ, Nathan SD, Browning RF, Barnett 
SD, Ahmad S, Shorr AF: The distance-satura-
tion product predicts mortality in idiopathic 
pulmonary fibrosis. Respir Med 2006; 100: 
 1734–1741. 
 
 5 Thabut G, Christie JD, Ravaud P, Castier Y, 
Dauriat G, Jebrak G, Fournier M, Leseche G, 
Porcher R, Mal H: Survival after bilateral ver-
sus single-lung transplantation for idiopathic 
pulmonary fibrosis. Ann Intern Med 2009; 
 151: 767–774. 
 6 Christie JD, Edwards LB, Kucheryavaya AY, 
Benden C, Dipchand AI, Dobbels F, Kirk R, 
Rahmel AO, Stehlik J, Hertz MI; Internation-
al Society for Heart and Lung Transplanta-
tion: The Registry of the International Society 
for Heart and Lung Transplantation: 29th 
adult lung and heart-lung transplant re-
port-2012. J Heart Lung Transplant 2012; 31: 
 1073–1086. 
 7 Fernandez Perez ER, Daniels CE, Schroeder 
DR, St Sauver J, Hartman TE, Bartholmai BJ, 
Yi ES, Ryu JH: Incidence, prevalence, and 
clinical course of idiopathic pulmonary fibro-
sis: a population-based study. Chest 2010; 137: 
 129–137. 
 8 Schwartz DA, Helmers RA, Galvin JR, Van 
Fossen DS, Frees KL, Dayton CS, Burmeister 
LF, Hunninghake GW: Determinants of sur-
vival in idiopathic pulmonary fibrosis. Am J 
Respir Crit Care Med 1994; 149: 450–454. 
 9 King TE Jr, Tooze JA, Schwarz MI, Brown KR, 
Cherniack RM: Predicting survival in idio-
pathic pulmonary fibrosis: scoring system 
and survival model. Am J Respir Crit Care 
Med 2001; 164: 1171–1181. 
 10 Collard HR, King TE Jr, Bartelson BB, Vour-
lekis JS, Schwarz MI, Brown KK: Changes in 
clinical and physiologic variables predict sur-
vival in idiopathic pulmonary fibrosis. Am J 
Respir Crit Care Med 2003; 168: 538–542. 
 11 Flaherty KR, Andrei AC, Murray S, Fraley C, 
Colby TV, Travis WD, Lama V, Kazerooni 
EA, Gross BH, Toews GB, Martinez FJ: Idio-
pathic pulmonary fibrosis: prognostic value 
